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SUMMARY An activation of T-cells that is restricted to the lung has been demonstrated in pulmo-
nary sarcoidosis. The role of blood monocytes (MO) and alveolar macrophages (AM) in this concept 
of compartmentalized inflammation has not yet been evaluated. In order to elucidate this question, 
we measured the release of tumor necrosis factor a (TNFa) and interleukin-1 (IL-1) by peripheral 
blood mononuclear cells (PBMNC) and AM in 43 patients with sarcoidosis (32 with active, 11 with 
inactive disease) without therapy and correlated the spontaneous monokine release to parameters 
of the T-cell alveolitis and the course of the disease. TNFa as well as IL-1 were spontaneously released 
by AM of the active group, i.e., 2,385 ± 735 pg/ml/106 cells/24 h and 7/12 (IL-1 Vtotal), respectively. 
Autologous PBMNC were quiescent, releasing only baseline levels of any monokine. AM were not 
activated in the inactive group, releasing 500 ± 212 pg/ml/106 cells/24 h TNFa, whereas 1/5 were 
IL-1-positive (p < 0.05 in both comparisons), which is within the range of the control group. Kinetic 
experiments revealed that the TNFa gene of AM is activated in vivo, resulting in TNFa mRNA-positlve, 
TNFa-releasing cells that, cultured in vitro, regulate the TNFa gene transcription down and cease 
to release TNFa. Interestingly, there is no stringent correlation between the spontaneous release 
of TNFa by AM and signs of T-cell activation as soluble interleukin-2 (IL-2) receptor serum concen-
tration, release of IL-2, and expression of IL-2 receptor by alveolar T-cells. Compartmentalized T-cell 
activation in active pulmonary sarcoidosis is therefore paralleled by the functional activation of 
AM. Analogous to T-cells of peripheral blood, MO are quiescent. This speaks in favor of a simultane-
ous activation of immune cells by the inflammatory milieu of the lower respiratory tract. 
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Introduction 
T u m o r necrosis factor a (TNFa) plays 
a key role as a mediator of inflamma-
tion and cellular immune response. It is 
primarily produced and secreted by acti-
vated macrophages and monocytes and 
exhibits an extensive array of biologic ac-
tivities. In addition to exerting a direct 
cytotoxic effect on tumor cells, it attracts 
and activates a variety of other cells, thus 
enhancing the inflammatory and im-
mune processes (1). T N F a apparently 
shares several bioactivities with inter-
leukin-1 (IL-1), and it is capable of in-
ducing IL-1 release (1). Interactions of 
interleukin-2 (IL-2) and its receptor (IL-
2R) with T N F a have recently been de-
scribed by several investigators demon-
strating the induction of T N F a produc-
tion in monocytes and macrophages by 
IL-2 (2) as well as the regulation of D N A -
binding proteins by T N F a , which con-
trol IL-2 receptor gene activation in hu-
man T-cells (1, 3). 
The most characteristic features of pul-
monary sarcoidosis are noncaseating 
granuloma and a T-lymphocyte/mono-
nuclear phagocyte alveolitis. Despite the 
systemic nature of the disease, activated 
T-cells are observed only in the affected 
organs, whereas T-cells of the peripheral 
blood remain quiescent (4-8). Evidence 
of T-cell activation has been provided by 
the spontaneous release of such media-
tors as y-interferon and IL-2, which re-
cruit and activate mononuclear phago-
cytes, resulting in the subsequent release 
of IL-1 and T N F a (9,10). Several studies 
have demonstrated that macrophage-
derived IL-1 and T N F a play an impor-
tant role in the induction and sustenance 
of the granuloma (11). 
Detailed analyses of the contribution 
of activated T-cells to the inflammatory 
process of sarcoidosis are provided by the 
literature. However, the alveolar macro-
phages represent the dominating cell 
population in sarcoid alveolitis. These 
cells are also activated and release medi-
ators as well as oxidants (8-10, 12). Re-
garding the activation status of periph-
eral blood monocytes, only a few studies 
are available, and conflicting results have 
been reported. Monitoring the sponta-
neous y-interferon, T N F a , and IL-1 re-
lease by monocytes, no differences were 
observed by several investigators between 
patients with sarcoidosis and normal 
control subjects (8, 13). In marked con-
trast, an increased release of radical ox-
idants by sarcoid blood monocytes has 
been reported (14). Thus, the question of 
an organ-restricted activation of the 
mononuclear phagocytes paralleling the 
compartmentalized activation of sarcoid 
T-cells remains open. In this context we 
asked the following questions: (7) Is the 
activation of alveolar macrophages in 
sarcoidosis paralleled by the activation 
of peripheral blood monocytes? (2) Is this 
activation due to a stimulus from the in-
flammatory milieu of the lower respira-
tory tract or is it a constitutive property 
of these cells? (3) Is there a concordant 
activation of the alveolar macrophage/ 
monocyte segment as well as the T-cell 
segment of the immune system? 
As an approach this study evaluates 
the spontaneous and LPS-induced T N F a 
and IL-1 release by alveolar macrophages 
and peripheral blood mononuclear cells 
of patients with active or inactive sarcoid-
osis and control subjects. The spontane-
ous T N F a release was compared with 
functional parameters of T-cell activation 
such as release of IL-2, expression of IL-2 
receptors on the cell surface, and soluble 
IL-2 receptor concentration in serum. 
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TABLE 1 
CHARACTERISTICS OF STUDY POPULATIONS 
Symptoms/Parameters 
Chest radiograph 
Bihilar adenopathy 
Progressing 
Stable/regressing 
Parenchymal involvement 
Progressing 
Stable/regressing 
Pulmonary function test 
Restrictive lung disease 
Progressing 
Stable/regressing 
Compliance^ 
Decreasing 
Stable/increasing 
DLCO* 
Decreasing 
Stable/increasing 
Symptoms 
Cough/dyspnea 
Fever 
Arthralgia 
Erythema nodosa 
Elevated serologic parameters 
Angiotensin-converting enzyme 
Neopterin 
Extrathoracic disease 
Uvea 
Liver 
Heart 
Skin 
Nervous system 
Active 
Sarcoidosis' 
(n = 32) 
26T 
4 
Inactive 
Sarcoidosis 
(n - 77) 
* The allocation of an individual patient in either group was based on the evaluation of the course 
of the disease over 1 to 2 months prior to the bronchoalveolar lavage 
t The number of patients presenting with the particular laboratory finding or symptom is given 
* Not all patients underwent these testings 
Methods 
Study Population 
The diagnosis of sarcoidosis was established 
in 43 patients using defined criteria, includ-
ing transbronchial biopsy (15). None of the 
patients received therapy at the time of inves-
tigation nor had they within the previous 2 
months. For the purpose of this study, the 
patients were allocated to groups of clinical-
ly active or inactive sarcoidosis based on newly 
observed or progressing pulmonary or general 
symptoms (dyspnea, cough, fever, arthralgia, 
uveitis, etc.), new or progressing abnormali-
ties in the pulmonary function test or the chest 
radiograph. The clinically active group con-
sisted of 32 patients; the clinically inactive 
group consisted of 11 patients. The clinical 
characteristics of the two groups are given in 
table 1. The two groups did not differ in age, 
sex, or smoking history (p > 0.02). Bronchoal-
veolar lavage (BAL) revealed equal volumes 
recovered in both groups, and on average the 
active group showed a significant increase in 
lymphocytes (20.9% versus 13.4%, p < 0.05) 
with an increase in the ratio of CD4 (helper 
T-cells) to CD8 (suppressor/cytotoxic T-cells) 
(4.2 in the active versus 2.7 in the inactive 
group). Eight patients who underwent bron-
choscopy for diagnostic reasons and who were 
free of interstitial lung diseases retrospectively 
or had benign neoplasia served as control sub-
jects. Peripheral blood was drawn from 18 
healthy subjects for control purposes. 
Preparation of Bronchoalveolar and 
Blood Mononuclear Cells 
Bronchoalveolar cells were obtained by BAL 
as described elsewhere (16). Recovered BAL 
fluid was filtered and centrifuged at 1,500 
rpm, and the cells were washed three times 
with RPMI 1640 (Seromed, Berlin, Germa-
ny). Pure A M (> 95%) were prepared by sub-
sequent 2-h plastic adherence (17). Blood was 
obtained by venipuncture, and mononuclear 
cells (PBMNC) were isolated by Ficoll Hy-
paque gradient centrifugation (17). 
Cell Culture 
Cells were resuspended to a final concentra-
tion of 106 cells/ml in RPMI 1640 with 10% 
fetal calf serum (Seromed), 200 mM gluta-
mine (Seromed), 1% HEPES (Seromed), and 
50 ug/ml gentamycin (Seromed). To measure 
spontaneous TNFa release, cells were cultured 
without any added stimulus. Control cultures 
received Salmonella abortus equi endotoxin 
(LPS) (Sigma, Miinchen, Germany), lug/ml. 
The plates were incubated for 24 h, and the 
supernatants were collected and stored fro-
zen at - 2 0 ° C. To investigate the spontane-
ous release of TNFa in vitro as a function 
of time, two cultures were initiated simultane-
ously. Three hours prior to the end of the cul-
ture cells were washed, and fresh culture medi-
um was added. At the end of the culture su-
pernatants were harvested and stored frozen 
until tested. An additional culture was stimu-
lated with LPS (1 ug/ml) after 6 h without any 
stimulus, and the supernatants were harvest-
ed after 18 h. 
Cytokine Assays 
TNFa was determined using a previously de-
scribed enzyme-linked immunosorbent assay 
(ELISA) (18) with slight modifications. Brief-
ly, 96-well flat-bottom plates (Immunoplates; 
Flow Laboratories, Meckenheim, Germany) 
were coated with 5 ug/ml monoclonal anti-
recombinant human TNFa (rhTNFa) anti-
body (clone 195; kindly provided by Dr. E. 
Schlick, Knoll AG, Ludwigshafen, Germany). 
Serial dilutions of the test samples in phos-
phate-buffered saline/0.1% bovine serum al-
bumin (BSA; Merck, Darmstadt, Germany) 
were applied to the plates for 2 h afterwards. 
The captured TNFa was detected by a biotin-
conjugated protein A (Sigma) purified poly-
specific rabbit anti-rhTNFa antibody and 
streptavidin-peroxidase (Boehringer, Mann-
heim, Germany). Absorption curves obtained 
with the test samples were compared with a 
standard curve obtained with rhTNFa (kind-
ly provided by Dr. E. Schlick, Knoll AG), and 
the TNFa content was expressed as pg/ml. 
The lower limit of sensitivity was 250 pg/ml. 
IL-1 was determined using the standard 
costimulaton assay with thymocytes of C3H/ 
HeJ mice (19). Alternatively, a commercially 
available IL-1 ELISA for IL-10 (Interleukin-
10 ELISA Kit; Cistron, Pine Brook, NJ) was 
used. 
IL-2 biologic activity was determined by 
the concentration-dependent proliferation of 
the murine cytotoxic T-lymphocyte line 
(CTLL). Proliferation was measured by bro-
modesoxyuridine (BrdU) incorporation de-
tected by an ELISA using a monoclonal anti-
BrdU antibody (20). The IL-2 units present 
were quantified by using probit analysis with 
a 20% intercept (21) and expressed as inter-
national units of IL-2 released by 10* T-cells 
in BAL. International IL-2 units were derived 
from an arbitrary IL-2 standard that was 
calibrated with the International IL-2 Stan-
dard (National Institute for Biological Stan-
dards and Controls, UK). 
Northern Blot 
For Northern analysis total cellular RNA was 
prepared using guanidine-thiocyanate lysis. 
RNA samples were size-fractionated by elec-
trophoresis in 1% agarose gels containing 
formaldehyde and transferred to nylon filters 
(Genofit, Heidelberg, Germany). Hybridiza-
tion was performed as described by using the 
750 bp EcoRI-fragment of the coding region 
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Fig. 1. Spontaneous (left panel) and LPS-induced (right panel) release of TNFa by alveolar macrophages (AM) 
in patients with sarcoidosis and in control subjects. 
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Fig. 2. Spontaneous (leftpanel) and LPS-induced (rightpanel) release of TNFa by peripheral blood mononuclear 
cells (PBMNC) in patients with sarcoidosis and in control subjects. 
of human TNFa cDNA as probe. The probe 
was labeled by the random primer method. 
Determination of Soluble 
IL-2R in Serum 
The sIL-2R was evaluated by a sandwich 
enzyme-linked immunosorbent assay (ELISA) 
employing two monoclonal antibodies direct-
ed against different epitopes of the IL-2 recep-
tor (Cellfree Interleukin-2 Receptor Test Kit; 
T Cell Sciences, Cambridge, MA). 
Immunoperoxidase Technique 
BAL cells were fixed on polylysine-coated 
slides (Bio-Rad Laboratories, Richmond, CA) 
and developed with a peroxidase-antiperoxi-
dase technique using monoclonal antibodies 
directed against CD3, CD4, CD8, and CD25 
(Ortho Diagnostic Systems, Neckargemund, 
Germany) and HLA-DR (Becton Dickinson, 
Heidelberg, Germany) at concentrations sug-
gested by the suppliers. 
Statistical Analysis 
Data are expressed as mean ± SEM. Com-
parisons were performed using the Mann 
Whitney U-test; p values of less than 0.05 were 
considered significant. 
Results 
Monokine Release by Alveolar 
Macrophages and Peripheral 
Blood Mononuclear Cells 
Spontaneous T N F a release by A M was 
found to a significant greater extent in 
patients with active sarcoidosis than in 
those with inactive disease (figure 1). The 
average was 2,385 ± 735 pg/ml in the 
active versus 500 ± 212 pg/ml in the in-
active group. This difference is of high 
statistical significance (p < 0.01). The A M 
of the control group released 285 ± 102 
pg/ml T N F a , which is in the range of pa-
tients with inactive sarcoidosis (p > 0.02). 
A comparison of T N F a production by 
A M after stimulation with L P S also 
showed a significantly higher release in 
active compared with inactive sarcoidosis 
(26,416 ± 3,283 pg/ml versus 14,957 ± 
3,653 pg/ml; p < 0.05) (figure 1). No 
difference emerged in comparing patients 
with inactive disease with control sub-
jects (17,189 ± 3,670 pg/ml; p > 0.2). 
Although lung macrophages from pa-
tients with active disease released signif-
icantly higher amounts of T N F a than did 
those from patients with inactive sarcoid-
osis and control subjects, the autologous 
P B M N C released comparable quantities 
in patients with sarcoidosis and in 15 
healthy subjects. The spontaneous release 
was 384 ± 144 pg/ml in patients with 
active, 684 ± 186 pg/ml in those with 
inactive sarcoidosis, and 378 ± 186 
pg/ml in control subjects (p > 0.2 for all 
comparisons) (figure 2). The LPS-stim-
ulated release of T N F a by peripheral 
blood mononuclear cells as well did not 
differ between the three study groups; 
4,959 ± 722 pg/ml in patients with ac-
tive and 3,709 ± 1,272 pg/ml in those 
with inactive sarcoidosis, and 3,725 ± 
449 pg/ml in normal subjects (p > 0.2, 
for all comparisons) (figure 2). 
Spontaneous T N F a release by A M was 
not only observed in patients with sarcoi-
dosis. Evaluation of T N F a release by A M 
in patients with idiopathic pulmonary 
fibrosis (IPF) (n = 9) and tuberculosis 
(n = 2) also demonstrated a spontane-
ous production of T N F a in three of nine 
patients with IPF (1,023/703/14,000 pg/ 
ml) and in the two patients with pulmo-
nary tuberculosis (8,350 and 1,658 pg/ml). 
Six of nine patients with IPF and two 
patients with pneumonia tested negative 
for spontaneous T N F a release by A M . 
In order to determine if the T N F a re-
lease in sarcoidosis is paralleled by the 
release of IL-1, we investigated both spon-
taneous and LPS-induced IL-1 release by 
A M and P B M N C of patients with active 
or inactive sarcoidosis. Increased spon-
taneous IL-1 release by A M was observed 
in 7 of 12 patients with active disease and 
in one of five with inactive disease (p < 
0.05) (figure 3). The autologous P B M N C 
in both groups did not release any de-
tectable 11-1 spontaneously (figure 3). Af-
ter LPS-stimulation the A M of active sar-
coidosis released significantly higher 
amounts of IL-1 than did those of inac-
tive disease. No difference concerning the 
stimulated release of P B M N C was ob-
served in either group. To check for ar-
tifacts that might alter the IL-1 data ob-
tained by the bioassay in four patients 
with active disease and TNFa-positive al-
veolitis and in two patients with inactive 
disease and T N F a negative alveolitis, IL-
1 (3 was measured by an E L I S A . In all four 
patients with T N F a in the AM-superna-
tant IL- lp could be detected as well (20 
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Fig. 3. Spontaneous IL-1 release by 
bronchoalveolar lavage cells (lung) and 
peripheral blood mononuclear cells 
(blood) of patients with active or inac-
tive sarcoidosis. Control experiments 
were performed to demonstrate that in 
case of no spontaneous IL-1 release the 
cells were capable of secreting IL-1 af-
ter stimulation. In all control experiments 
an IL-1 release was observed after in 
vitro stimulation with 1 pig LPS/ml (data 
not shown). 
to 4,432 pg/ml). No IL-1 was detectable 
in the supernatants of the two patients 
with inactive disease. 
Time-dependent Changes of 
Spontaneous TNFa Release by 
Alveolar Macrophages of 
Patients with Active Sarcoidosis 
To evaluate the hypothesis that height-
ened T N F a production by sarcoid A M 
in active disease may represent the con-
sequence of a constitutive or a regulated 
activation of the cells, we investigated the 
time-dependent changes of spontaneous 
T N F a release 3 and 6 h after initiation 
of the cell culture. During the in vitro cul-
ture a considerable decrease of T N F a 
secretion was observed (figure 4). A l -
though the highest amount of T N F a was 
released within the first 3 h after recov-
ery of the cells, a significant decline was 
observed during the following 3 h. How-
ever, when the cells were cultured in the 
presence of a stimulus they recurrently 
produced high levels of T N F a . 
To investigate T N F a gene expression 
in vitro as a function of time we evaluat-
ed A M for the presence of m R N A tran-
scripts immediately after the cells were 
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Fig. 4. Time-dependent changes of spontaneous TNFa 
release by sarcoid alveolar macrophages (AM) during 
in vitro culture. After 6 h, 1 ng LPS/ml was added to 
the culture. (Two of two experiments are depicted.) 
n - 4 
recovered from the lung and after 24 h 
in culture. Immediately after removal 
from the lung, the cells contained an 
abundance of T N F a transcripts (figure 
5, lane 0 hr). In the absence of stimu-
lating agents, however, the amount of 
m R N A transcripts vanished over time 
(figure 5, lane 24 hr). In marked contrast, 
the cells maintained their T N F a gene 
transcription during the entire culture 
period when cultured in the presence of 
a stimulus (figure 5, lane 24 hr + LPS) . 
Correlation between TNFa Release 
and Different Parameters of T-Cell 
Activation in Patients with 
Active Sarcoidosis 
Lung T-cells of patients with active sar-
coidosis express typical signs of activa-
tion as spontaneous release of IL-2 and 
expression of IL-2R. Interactions of IL-2 
0 24 24 
+LPS 
hr 
Fig. 5. Northern analysis of TNFa gene expression by 
sarcoid alveolar macrophages as a function of time. Im-
mediately after removal from the lung (0 hr), after 24 h 
in vitro culture without (24 hr) and with 1 mg LPS/ml 
(24 hr + LPS). (One typical experiment of four is shown.) 
and its receptor with T N F a have been 
reported. Therefore, we investigated the 
correlation between spontaneous T N F a 
release by A M and spontaneous IL-2 
release and IL-2R expression by B A L 
T-lymphocytes and soluble IL-2R serum 
levels in 21 patients with sarcoidosis (16 
of the active and 5 of the inactive group). 
In none of the tested combinations could 
a correlation coefficient higher than 0.2 
be observed. The correlation coefficient 
of TNFa / s IL -2R serum concentration 
was 0.06 (n = 22) (figure 6A), T N F a / 
IL-2R-positive B A L lymphocytes was 
0.15 (n = 36), (figure 6B), and T N F a / 
IL-2 release by B A L lymphocytes was 
0.10 (n = 21), (figure 6C), respective-
ly. To further analyze the interrelation 
between IL-2 and T N F a , we subdivided 
the patients according to their sponta-
neous I L - 2 / T N F a release. Eight of 21 pa-
tients produced IL-2 (> 1 U/ml /10 6 B A L 
T-cells/24 h) as well as T N F a (> 700 
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Fig. 6. Correlation of different parameters of T-cell ac-
tivation (soluble interleukin-2 receptor (IL-2R] serum con-
centration, percent surface IL-2R-positive lymphocytes 
in bronchoalveolar lavage [BAL] fluid, IL-2 release by 
BAL lymphocytes) with spontaneous TNFa release by 
sarcoid alveolar macrophages (AM). 
pg/ml/10 6 A M / 2 4 h; 700 pg/ml corre-
sponds to the mean plus 2 SD of 7 con-
trol subjects), 3 of 21 patients produced 
neither IL-2 nor T N F a , 7 of 21 released 
T N F a but no IL-2, and 3 of 21 released 
IL-2 but no T N F a . 
In the inactive group alveolitis was 
positive in one patient for both media-
tors, in one patient for IL-2 only, and it 
was positive for any mediator in the re-
maining three patients. In the active 
group seven patients were positive for 
both cytokines, seven for T N F a but not 
for IL-2, and two were IL-2-positive but 
TNFa-negative. 
The patients with active disease ex-
hibited an increased C D 4 / C D 8 ratio to-
gether with a spontaneous T N F a release 
by A M . However, there was no correla-
tion between these two parameters in ei-
ther the active (r = -0.08, n = 28) or 
the inactive group (r = -0.02, n = 10). 
Discussion 
T N F a is an important biologic media-
tor that is secreted by activated A M and 
monocytes. In addition to activated 
T-cells, A M are the second but numeri-
cally dominating cell population in sar-
coidosis. Our results confirm and extend 
the observation of the activation of these 
cells as reflected by their capacity for 
monokine release. The data presented 
demonstrate that A M of patients with 
active sarcoidosis spontaneously release 
significantly higher amounts of T N F a 
and IL-1 than do those of patients with 
inactive disease or control subjects. In 
the present study the heightened level of 
spontaneous T N F a secretion by A M was 
paralleled by an elevated spontaneous 
IL-1 release in 7 of 12 of the patients with 
active disease tested for both monokines. 
Our findings are in agreement with those 
of other investigators, who reported a sig-
nificantly higher spontaneous release of 
T N F a , 11-1, and y-interferon by sarcoid 
A M than by normal A M (8, 10, 22). On 
the other hand, several investigators 
could not demonstrate any differences 
between sarcoid and normal A M regard-
ing the spontaneous secretion of the 
monokines T N F a and IL-1 (9, 13, 23). 
These discrepancies might be explained 
by monokine inhibitors, which are known 
to be released by A M and which might 
influence the detection of these small 
amounts of monokines by bioassays (24, 
25). As can be expected the spontaneous 
T N F a release by A M is not an exclusive 
characteristic of sarcoid alveolitis; it can 
be observed as well in diseases associat-
ed with A M activation by known or un-
known agents such as tuberculosis and 
IPF. T N F a has been demonstrated to be 
involved in bleomycin- as well as silica-
induced pulmonary fibrosis and in the 
generation of granulomata (11, 26). 
In marked contrast to A M , no dif-
ferences between patients and control 
subjects emerged when the spontane-
ous monokine release by autologous 
P B M N C was tested. Our data suggest a 
restricted activation of the mononuclear 
phagocytes of the affected organ, i.e., the 
lung, whereas the mononuclear blood 
cells remain quiescent. This observation 
is corroborated by the study of Robin-
son and coworkers (8) who reported an 
increased y-interferon release by sarcoid 
A M compared with that by normal A M . 
This spontaneous release appeared to be 
compartmentalized to the lung in that the 
blood mononuclear cells spontaneously 
released little or no y-interferon (8). A n 
in vitro anergy of sarcoid peripheral 
blood cells reflected in the reduced IL-1 
and IL-2 production was observed by 
Hudspith and coworkers (27). Spatafora 
and colleagues (13) demonstrated small 
amounts of spontaneously produced 
T N F a by blood monocytes of sarcoid pa-
tients and normal control subjects, but 
without any difference between both. 
Using oxygen radical release to identify 
activated cells, it has been shown that sar-
coid A M as well as peripheral blood 
monocytes are activated (12,14). Regard-
ing the monokine release, our data do 
not confirm this activation. Thus, the ex-
aggerated oxygen radical release suggests 
a systemic monocyte activation in sar-
coidosis. A feasible explanation of this 
contradiction may be seen in the short-
term activation of the monokine gene ex-
pression after cell stimulation (1, 3). 
Studies on the molecular level demon-
strated that maximal expression of T N F a 
gene is reached within 2 h after stimula-
tion with L P S . Cytoplasmic T N F a was 
detected as early as 1 h after L P S stimu-
lation, culminating during the next 2 h 
and followed by a decline (recently re-
viewed in 1 and 3). In this context our 
results indicate that the heightened spon-
taneous T N F a release in active sarcoid-
osis is the consequence of an in vivo ac-
tivation step just prior to the removal of 
the cells from the lung. Because the 
highest amount of T N F a is produced 
during the first 3 h of in vitro culture fol-
lowed by a sharp decline, it can be con-
cluded that T N F a release is regulated in 
a physiologic manner in those cells and 
that the putative agent causing sarcoid-
osis does not interfere with the regula-
tion of the T N F a gene (figure 4). This 
concept is further corroborated by the 
decay of T N F a m R N A in the in vitro cul-
ture in the absence of any stimulation 
(figure 5). 
Our observation that LPS-stimulated 
sarcoid A M of patients with active sar-
coidosis produce significantly more T N F a 
than do A M of normal subjects and of 
those with inactive disease is in accor-
dance with the literature and suggests that 
in sarcoidosis A M become primed local-
ly (9,13). The increased ability to secrete 
T N F a after endotoxin stimulation may 
represent an additional marker of acti-
vation that is restricted to the lung. How-
ever, the mechanism by which sarcoid 
A M are primed for elevated T N F a secre-
tion remains open. Cytokines such as 
interleukin-2 and y-interferon, which are 
produced locally by activated lung T-cells 
in sarcoidosis may represent the initia-
tive agents of T N F a production. In hu-
man blood monocytes and A M , IL-2 is 
a strong signal for T N F a induction (2). 
We therefore investigated the interrela-
tion between IL-2 and T N F a , which are 
both spontaneously released in patients 
with active disease. Unexpectedly, we 
could not establish a correlation between 
these two parameters (r = 0.1) Eight of 
21 (38%) patients released both cytokines 
simultaneously, whereas 7 of 21 (33%) 
secreted only T N F a , 3 of 21 (14%) only 
IL-2, and 3 of 21 (14%) neither of both. 
The finding of induction of T N F a by 
IL-2 has established an additional lym-
phokine-macrophage link (2), but cur-
rently the role of IL-2 in the induction 
of T N F a in pulmonary sarcoidosis re-
mains a subject of speculation. In addi-
tion to the lacking correlation between 
IL-2 and T N F a , we could not find any 
correlation between T N F a and other 
markers of T-cell activation such as IL-2R 
surface expression by B A L T-lympho-
cytes and soluble IL-2R serum concen-
tration, which represent useful tools for 
measuring T-cell activation (28) as well 
as clinical activity of the disease (29). It 
is interesting to observe that in only 7 of 
16 patients with active sarcoidosis, T N F a 
and IL-2 are simultaneously released by 
the alveolar immune cells. 
Accessory functions that are provided 
by the cells of the mononuclear phago-
cytic lineage are required by most types 
of cellular and immune processes. The 
observation that these cells are compart-
mentalized and activated to release large 
amounts of monokines such as IL-1 and 
T N F a spontaneously therefore suggests 
that they participate in the pathogenesis 
of sarcoidosis not only as a building 
block in the formation of granulomata 
but also in the maintenance of the in-
flammatory processes characteristic of 
the disorder. 
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